Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 40.60 1.50% 0.60
RYTM closed up 1.5 percent on Monday, March 18, 2024, on 74 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness 1.50%
New Downtrend Bearish 1.45%
Multiple of Ten Bullish Other 1.45%
Oversold Stochastic Weakness 1.45%
NR7 Range Contraction -0.90%
Narrow Range Bar Range Contraction -0.90%
Inside Day Range Contraction -0.90%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 13 hours ago
Rose Above Previous Day's High about 13 hours ago
Outside Day about 13 hours ago
60 Minute Opening Range Breakout about 13 hours ago
Rose Above 10 DMA about 13 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Rhythm Pharmaceuticals, Inc. Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Peptides Metabolic Disorders Peptide Hormones Genetic Disorder Monogenic Leptin Melanocortin

Is RYTM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 52.57
52 Week Low 15.5001
Average Volume 651,738
200-Day Moving Average 30.58
50-Day Moving Average 44.26
20-Day Moving Average 43.06
10-Day Moving Average 40.83
Average True Range 2.22
RSI (14) 39.76
ADX 25.94
+DI 12.37
-DI 22.25
Chandelier Exit (Long, 3 ATRs) 45.15
Chandelier Exit (Short, 3 ATRs) 46.13
Upper Bollinger Bands 48.55
Lower Bollinger Band 37.57
Percent B (%b) 0.28
BandWidth 25.50
MACD Line -1.51
MACD Signal Line -1.18
MACD Histogram -0.3282
Fundamentals Value
Market Cap 2.4 Billion
Num Shares 59.1 Million
EPS -3.24
Price-to-Earnings (P/E) Ratio -12.53
Price-to-Sales 50.00
Price-to-Book 15.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.56
Resistance 3 (R3) 42.49 41.77 42.23
Resistance 2 (R2) 41.77 41.27 41.80 42.13
Resistance 1 (R1) 41.19 40.96 41.48 41.25 42.02
Pivot Point 40.46 40.46 40.61 40.50 40.46
Support 1 (S1) 39.88 39.96 40.17 39.95 39.18
Support 2 (S2) 39.16 39.65 39.19 39.07
Support 3 (S3) 38.57 39.16 38.97
Support 4 (S4) 38.64